Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials-Reference-Cited by-同舟云学术

Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

Published:2024-03 Issue:3 Volume:14 Page:729-743
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Sun Rui,Bustamante Mercedes,Gurusamy Venkatesh Kumar,Lebwohl Mark,Gottlieb Alice B.,Mease Philip J.,Deodhar Atul,Bao Weibin,Mendelson Meryl,Porter Brian,Chand Deepa,Dong Victor

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01122-2.pdf

Reference27 articles.

1. Secukinumab Summary of Product Characteristics (SmPC). Basel: Novartis Pharma AG.

2. Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401:747–61.

3. Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21-s40.

4. Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clin Rev Allergy Immunol. 2022;62:413–31.

5. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–90.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies;Expert Opinion on Drug Safety;2024-09-12